Efecto de golimumab intravenoso en la fatiga y la relación con la respuesta clínica en adultos con espondilitis anquilosante activa en el estudio de fase 3 estudio de fase 3 GO-ALIVE
Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y
Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.
This post-hoc analysis of the GO-ALIVE study specifically investigates fatigue symptoms related to AxSpA. Participants were randomised 1:1 to golimumab or a placebo, with the placebo group introduced to golimumab in Week 16. The placebo group had similar improvements to the treatment group at Week 52.
Keywords:
